20 Sep, 2022 | New products

The Creoptix® WAVE system enables high-sensitivity, label-free analysis of binding kinetics and affinity analysis for drug discovery.

Conventional bioassays, like Surface Plasmon Resonance (SPR) have relied on enzyme or fluorescent labels to detect and monitor biomolecular interactions, but these methods tend to capture just one point in time and are fraught with non-specific binding issues that can skew results.

Malvern Panalytical’s Creoptix® WAVEsystem, is a label-free technology that delivers deeper insight into previously undetectable interactions. Kinetic rate parameters and affinity constants (ka, kd, KD) along with binding specificity are derived in real-time from even the most challenging sample types in a wide range of biological matrices.

The power behind the Creoptix WAVEsystem is in the patented Grating-Coupled Interferometry (GCI) technology and non-clog WAVEchip microfluidics system. GCI is unique and measures the evanescent wave across the entire sensor surface and isn’t affected by temperature drifts or vibrations, allowing for more sensitive measurement.  The kinetics of weakly binding fragments and large molecules with high affinity and slow dissociation can be measured simply (even native proteins in complex matrices) without purification. The waveRAPID method can also be used to increase throughput, particularly in screening applications, by generating a pulsating concentration profile. Calibration-Free Concentration Analysis (CFCA) offers a reliable, quick and easy calibration-free approach to quantify active protein concentration.

For further details contact us